Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease

• Tiziana Life Sciences initiated dosing for the final patient in its Phase 2 trial of intranasal foralumab for early/mild Alzheimer's disease.
• Enrollment is complete; topline results are expected in the first quarter of 2027.
• The placebo-controlled trial evaluates safety and potential efficacy, testing foralumab alone or alongside anti-amyloid therapies.
• Key assessments include brain inflammation, cognitive function and biomarkers of Alzheimer's pathology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610160700OMX_____CNEWS_EN_GNW9847180_en) on October 16, 2026, and is solely responsible for the information contained therein.